D1.1 First set of recommendations for RDCTs (to be implemented in the pan-EU pilot DCT)

Amy Rogers; Isla Mackenzie; Hawkins Kimberley

D1.1 First set of recommendations for RDCTs (to be implemented in the pan-EU pilot DCT)

Amy Rogers (Lead / Corresponding author), Isla Mackenzie (Lead / Corresponding author), Hawkins Kimberley

Molecular and Clinical Medicine

Research output: Book/Report › Other report

Abstract

Clinical trials are a crucial step in the development and testing of medical treatments. They are essential to ensure that new treatments are safe and effective.

Traditionally, clinical trials have taken place in hospitals or other research sites, often requiring participants to attend several face-to-face study visits. While these trials produce results, they can do so at a great burden to participants and risk excluding people who are unable or unwilling to travel to study visits.

Remote decentralised clinical trials (RDCTs) are one way to make trials more accessible. RDCTs are centred around participants. Using technology can allow people to take part in clinical trials in their own home with no need to travel to attend study visits or to take substantial time off work or away from family. RDCTs have the potential to make taking part in a clinical trial simple and convenient.

These draft recommendations are based on in-depth research, conducted over a 12-month period, into remote decentralised clinical trial methods. They apply to all aspects of RDCTs from design, planning and set-up to close-out and reporting.

3 Key Recommendations
Answer an important research question
Keep the focus on participants
Simplify the participant experience whilst maintaining quality and scientific rigour

Full recommendations will be published at the end of the IMI Trials@Home project in 2024.

Original language	English
Publisher	Trials@Home
Number of pages	46
Publication status	Published - 26 Aug 2020

Keywords

Clinical trial methodology
Decentralised clinical trials

ASJC Scopus subject areas

Medicine(all)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

https://trialsathome.com/first-set-of-recommendations-for-rdcts-d1-1/

1 Active

Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials (Joint with 30 other participants, University Medical Centre Utrecht as lead)
MacDonald, T. & Mackenzie, I.
COMMISSION OF THE EUROPEAN COMMUNITIES
1/09/19 → 31/08/24
Project: Research

3 Article
2 Other contribution

A secondary qualitative analysis of stakeholder views about participant recruitment, retention, and adherence in decentralised clinical trials (DCTs)
Coyle, J., Rogers, A., Copland, R., De Paoli, G., MacDonald, T. M. & Mackenzie, I. S., 30 Jul 2022, In: Trials. 23, 11 p., 614.
Research output: Contribution to journal › Article › peer-review

Open Access
File
9 Downloads (Pure)
A Systematic Review of Methods used to Conduct Decentralised Clinical Trials
Rogers, A., De Paoli, G., Subbarayan, S., Copland, R., Harwood, K., Coyle, J., Mitchell, L., MacDonald, T. M. & Mackenzie, I. S., Jun 2022, In: British Journal of Clinical Pharmacology. 88, 6, p. 2843-2862 20 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
8 Citations (Scopus)

128 Downloads (Pure)
Learning from remote decentralised clinical trial experiences: a qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders
Coyle, J., Rogers, A., Copland, R., De Paoli, G., MacDonald, T. M. & Mackenzie, I. S., Mar 2022, In: British Journal of Clinical Pharmacology. 88, 3, p. 1031-1042 12 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
9 Citations (Scopus)

75 Downloads (Pure)

Cite this

@book{38e3abdb60a9406caf8148aa3da63b76,

title = "D1.1 First set of recommendations for RDCTs (to be implemented in the pan-EU pilot DCT)",

abstract = "Clinical trials are a crucial step in the development and testing of medical treatments. They are essential to ensure that new treatments are safe and effective.Traditionally, clinical trials have taken place in hospitals or other research sites, often requiring participants to attend several face-to-face study visits. While these trials produce results, they can do so at a great burden to participants and risk excluding people who are unable or unwilling to travel to study visits.Remote decentralised clinical trials (RDCTs) are one way to make trials more accessible. RDCTs are centred around participants. Using technology can allow people to take part in clinical trials in their own home with no need to travel to attend study visits or to take substantial time off work or away from family. RDCTs have the potential to make taking part in a clinical trial simple and convenient.These draft recommendations are based on in-depth research, conducted over a 12-month period, into remote decentralised clinical trial methods. They apply to all aspects of RDCTs from design, planning and set-up to close-out and reporting. 3 Key Recommendations Answer an important research question Keep the focus on participants Simplify the participant experience whilst maintaining quality and scientific rigour Full recommendations will be published at the end of the IMI Trials@Home project in 2024. ",

keywords = "Clinical trial methodology, Decentralised clinical trials",

author = "Amy Rogers and Isla Mackenzie and Hawkins Kimberley",

note = "This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No . This Joint Undertaking receives support from the European Union{\textquoteright}s Horizon 2020 research and innovation programme and EFPIA.",

year = "2020",

month = aug,

day = "26",

language = "English",

publisher = "Trials@Home",

}

TY - BOOK

T1 - D1.1 First set of recommendations for RDCTs (to be implemented in the pan-EU pilot DCT)

AU - Rogers, Amy

AU - Mackenzie, Isla

AU - Kimberley, Hawkins

N1 - This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No . This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.

PY - 2020/8/26

Y1 - 2020/8/26

N2 - Clinical trials are a crucial step in the development and testing of medical treatments. They are essential to ensure that new treatments are safe and effective.Traditionally, clinical trials have taken place in hospitals or other research sites, often requiring participants to attend several face-to-face study visits. While these trials produce results, they can do so at a great burden to participants and risk excluding people who are unable or unwilling to travel to study visits.Remote decentralised clinical trials (RDCTs) are one way to make trials more accessible. RDCTs are centred around participants. Using technology can allow people to take part in clinical trials in their own home with no need to travel to attend study visits or to take substantial time off work or away from family. RDCTs have the potential to make taking part in a clinical trial simple and convenient.These draft recommendations are based on in-depth research, conducted over a 12-month period, into remote decentralised clinical trial methods. They apply to all aspects of RDCTs from design, planning and set-up to close-out and reporting. 3 Key Recommendations Answer an important research question Keep the focus on participants Simplify the participant experience whilst maintaining quality and scientific rigour Full recommendations will be published at the end of the IMI Trials@Home project in 2024.

AB - Clinical trials are a crucial step in the development and testing of medical treatments. They are essential to ensure that new treatments are safe and effective.Traditionally, clinical trials have taken place in hospitals or other research sites, often requiring participants to attend several face-to-face study visits. While these trials produce results, they can do so at a great burden to participants and risk excluding people who are unable or unwilling to travel to study visits.Remote decentralised clinical trials (RDCTs) are one way to make trials more accessible. RDCTs are centred around participants. Using technology can allow people to take part in clinical trials in their own home with no need to travel to attend study visits or to take substantial time off work or away from family. RDCTs have the potential to make taking part in a clinical trial simple and convenient.These draft recommendations are based on in-depth research, conducted over a 12-month period, into remote decentralised clinical trial methods. They apply to all aspects of RDCTs from design, planning and set-up to close-out and reporting. 3 Key Recommendations Answer an important research question Keep the focus on participants Simplify the participant experience whilst maintaining quality and scientific rigour Full recommendations will be published at the end of the IMI Trials@Home project in 2024.

KW - Clinical trial methodology

KW - Decentralised clinical trials

M3 - Other report

BT - D1.1 First set of recommendations for RDCTs (to be implemented in the pan-EU pilot DCT)

PB - Trials@Home

ER -

D1.1 First set of recommendations for RDCTs (to be implemented in the pan-EU pilot DCT)

Abstract

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Fingerprint

Projects

Trials@Home: Center of Excellence – Remote Decentralised Clinical Trials (Joint with 30 other participants, University Medical Centre Utrecht as lead)

Research output

A secondary qualitative analysis of stakeholder views about participant recruitment, retention, and adherence in decentralised clinical trials (DCTs)

A Systematic Review of Methods used to Conduct Decentralised Clinical Trials

Learning from remote decentralised clinical trial experiences: a qualitative analysis of interviews with trial personnel, patient representatives and other stakeholders

Cite this